{"disease":{"id":"metastatic-castration-resistent-prostate-cancer","name":"metastatic castration resistent prostate cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04139772","title":"Docetaxel or Hormone Therapy as Second Line Treatment in Patients With Asymptomatic or Oligosymptomatic Metastatic Castration-resistent Prostate Cancer (mCRPC) Progressing After Abiraterone or Enzalutamide.","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":18,"lead_sponsor_name":"National Cancer Institute, Naples","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}